Marshall Edwards, Inc. Ovarian Cancer Drug Trial Shows Dismal Results, Shares Plummet (MSHL)
06/01/2010 - Shares of biotech group Marshall Edwards, Inc. (NASDAQ:MSHL) nose-dived about 50% to $2.03 earlier Tuesday afternoon, after the company reported its final results from a halted Phase III clinical study.
Data from the trial showed that the phenoxodiol drug did not slow the progress of ovarian cancer and did not notably extend the lives of patients.
Shares of Marshall Edwards continue to trade down 49.75% at $2.05.